# The Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2018, Regulation 3: Amendment of regulation 2


In regulation 2(2) (interpretation)—
(a) at the appropriate places insert—
““cannabis-based product for medicinal use in humans” means a preparation or other product, other than one to which paragraph 5 of part 1 of Schedule 4 applies, which—
(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);
(b) is produced for medicinal use in humans; and—
(c) is—
(i) a medicinal product, or
(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of a medicinal product;”;
““clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 2004;”;
““dronabinol” does not include any substance which—
(a) has the international non-proprietary name dronabinol (recommended by the World Health Organisation); and
(b) that is derived from cannabis, cannabis resin or their constituents, and stereoisomers of dronabinol are to be construed accordingly;”; and
““medicinal product” has the same meaning as in the Human Medicines Regulations 2012;”.

---
Source: https://www.legislation.gov.uk/nisr/2018/173/regulation/3 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-amendment-no2-regulations-northern-ireland-2018/regulation-3
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

